Literature DB >> 15247704

A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.

Michael L Blute1, Bradley C Leibovich, John C Cheville, Christine M Lohse, Horst Zincke.   

Abstract

PURPOSE: We determined the primary pathological features of clear cell renal cell carcinoma that are predictive of positive regional lymph nodes at radical nephrectomy (RN) and developed a protocol for the selective use of extended lymph node dissection.
MATERIALS AND METHODS: We studied 1,652 patients who underwent RN for unilateral pM0 sporadic clear cell renal cell carcinoma between 1970 and 2000. A multivariate logistic regression model was used to determine the pathological features of the primary tumor that were associated with positive regional lymph nodes at RN.
RESULTS: There were 887 (54%) patients with no positive nodes (pN0), 57 (3%) with 1 positive node (pN1), 11 (1%) with 2 or more positive nodes (pN2) and 697 (42%) who did not have any lymph nodes dissected (pNx). Nuclear grade 3 or 4 (p <0.001), presence of a sarcomatoid component (p <0.001), tumor size 10 cm or greater (p = 0.005), tumor stage pT3 or pT4 (p = 0.017) and histological tumor necrosis (p = 0.051) were significantly associated with positive regional lymph nodes in a multivariate setting. These features can be used to identify candidates for extended lymph node dissection at the time of RN. For example, only 6 (0.6%) of the 1,031 patients with 0 or 1 of these features had positive lymph nodes at RN compared with 62 (10%) of the 621 patients with at least 2 of these features.
CONCLUSIONS: The primary tumor pathological features of nuclear grade, sarcomatoid component, tumor size, stage and presence of tumor necrosis can be used to predict patients at the greatest risk for regional lymph node involvement at RN.

Entities:  

Mesh:

Year:  2004        PMID: 15247704     DOI: 10.1097/01.ju.0000129815.91927.85

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  41 in total

Review 1.  [Lymph node dissection in patients with renal cell carcinoma].

Authors:  T Ebert; D Schnell; L Weissbach
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

2.  Best of the 2004 AUA Annual Meeting: Highlights from the 2004 Annual Meeting of the American Urological Association, May 8-13, 2004, San Francisco, CA.

Authors: 
Journal:  Rev Urol       Date:  2004

Review 3.  [Therapy strategies for advanced renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; C Adam; C G Stief
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

4.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

5.  Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.

Authors:  Malte Rieken; Stephen A Boorjian; Luis A Kluth; Umberto Capitanio; Alberto Briganti; R Houston Thompson; Bradley C Leibovich; Laura-Maria Krabbe; Vitaly Margulis; Jay D Raman; Mikhail Regelman; Pierre I Karakiewicz; Morgan Rouprêt; Mohammad Abufaraj; Beat Foerster; Mithat Gönen; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-11-07       Impact factor: 4.226

6.  Lymph node dissection in urological cancers: one topic, many controversies.

Authors:  Avinash Nehra; R Jeffrey Karnes; Giorgio Gandaglia; Alberto Briganti
Journal:  World J Urol       Date:  2017-03-01       Impact factor: 4.226

7.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

8.  Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Authors:  Benjamin T Ristau; Judi Manola; Naomi B Haas; Daniel Y C Heng; Edward M Messing; Christopher G Wood; Christopher J Kane; Robert S DiPaola; Robert G Uzzo
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450

Review 9.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

10.  Should patients undergoing surgery for renal cell carcinoma have a lymph node dissection?

Authors:  Stephen H Culp; Christopher G Wood
Journal:  Nat Clin Pract Urol       Date:  2009-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.